Is high-risk cutaneous squamous cell carcinoma of the head and neck a suitable candidate for current targeted therapies?

We demonstrate high proportion tumour suppressor loss of function mutations, high intratumour genetic heterogeneity, and presence of well recognised resistance mutations in treatment naïve primary HNcSCC. These factors pose challenges for successful utilisation of targeted therapies.